Fig. 5From: Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug reviewNumber of CDR submissions by the size of the largest clinical study considered in each submission. Numbers above columns indicate the number of submissionsBack to article page